Bladder preservation: Translating discovery for clinical impact in urothelial cancer.

Published on Apr 1, 2021in Urologic Oncology-seminars and Original Investigations2.882
· DOI :10.1016/J.UROLONC.2020.11.021
David T. Miyamoto29
Estimated H-index: 29
(Harvard University),
Philip Abbosh9
Estimated H-index: 9
(Fox Chase Cancer Center)
+ 1 AuthorsKent W. Mouw22
Estimated H-index: 22
(Brigham and Women's Hospital)
Muscle-invasive bladder cancer can be treated with either radical cystectomy or bladder preservation approaches, and there is a need for reliable biomarkers to guide the optimal choice of therapy. The recent elucidation of the genomic landscape and biological drivers of bladder cancer has enabled the identification of tumor molecular features that may be helpful in driving clinical decision-making. Here, we summarize recent efforts to develop molecular biomarkers that could be leveraged to guide therapeutic decisions, post-treatment monitoring, and the optimal use of bladder preservation approaches for the effective treatment of muscle-invasive bladder cancer.
#1Andrea NecchiH-Index: 35
#2Daniele RaggiH-Index: 19
Last. Ewan A. GibbH-Index: 27
view all 26 authors...
Abstract Background The PURE-01 study (NCT02736266) evaluated the use of pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective To evaluate the ability of molecular signatures to predict the pathological complete response (CR: ypT0N0) and progression-free survival (PFS) after pembrolizumab and RC. Design, setting, and participants We analyzed the expression data from patients with T2–4aN0M0 MIBC enrolled in the PURE-01 study (N=84) and from patients of a...
46 CitationsSource
#1Aurélie KamounH-Index: 3
Last. John N. Weinstein (University of Texas MD Anderson Cancer Center)H-Index: 127
view all 42 authors...
Abstract Background Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. Objective To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. Design, setting, and participants We used 1750 MIBC transcriptomic profiles from 16 published datasets and two a...
210 CitationsSource
#1Zhengjie Lin (SZU: Shenzhen University)H-Index: 6
#1Zhengjie Lin (SZU: Shenzhen University)H-Index: 1
Last. Zhou Liu (SZU: Shenzhen University)H-Index: 18
view all 6 authors...
Cancer remains the leading cause of death worldwide despite the enormous efforts that are made in the development of cancer biology and anticancer therapeutic treatment. Furthermore, recent studies in oncology have focused on the complex cancer metastatic process as metastatic disease contributes to more than 90% of tumor-related death. In the metastatic process, isolation and analysis of circulating tumor cells (CTCs) play a vital role in diagnosis and prognosis of cancer patients at an early s...
24 CitationsSource
#1Petros Grivas (Fred Hutchinson Cancer Research Center)H-Index: 22
#2Yohann Loriot (Institut Gustave Roussy)H-Index: 55
Last. Simon Chowdhury (Guy's and St Thomas' NHS Foundation Trust)H-Index: 32
view all 20 authors...
440Background: ATLAS (NCT03397394) evaluated the efficacy/safety of the PARP inhibitor (PARPi) rucaparib in patients (pts) with previously treated locally advanced/unresectable UC or mUC. Methods: ...
15 CitationsSource
#1Maria I. Carlo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 18
#2Vignesh Ravichandran (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 7
Last. Kenneth Offit (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 134
view all 38 authors...
PURPOSEUrothelial cancers (UCs) have a substantial hereditary component, but, other than their association with Lynch syndrome, the contribution of genetic risk factors to UC pathogenesis has not b...
27 CitationsSource
2 CitationsSource
#1Jason A. Efstathiou (Harvard University)H-Index: 55
#2Kent W. Mouw (Brigham and Women's Hospital)H-Index: 22
Last. David T. Miyamoto (Harvard University)H-Index: 29
view all 15 authors...
Abstract Background Bladder-sparing trimodality therapy (TMT) is an alternative to radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC), and biomarkers to inform therapy selection are needed. Objective To evaluate the prognostic value of immune and stromal signatures in MIBC treated with TMT. Design, setting, and participants We used a clinical-grade platform to perform transcriptome-wide gene expression profiling of primary tumors from 136 MIBC patients treated with TMT at a single...
59 CitationsSource
#1Emil Christensen (Aarhus University Hospital)H-Index: 10
#2Karin Birkenkamp-Demtröder (Aarhus University Hospital)H-Index: 29
Last. Lars Dyrskjøt (AU: Aarhus University)H-Index: 60
view all 34 authors...
PURPOSENovel sensitive methods for early detection of relapse and for monitoring therapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome for patients w...
102 CitationsSource
#1Panagiotis J. Vlachostergios (Cornell University)H-Index: 18
#2Bishoy Faltas (Cornell University)H-Index: 17
Purpose Urothelial carcinoma of the bladder (UCB) is a common malignancy with limited systemic treatment options in advanced stages. Despite recent advances in immunotherapy, the majority of patients do not respond to these treatments. There is an unmet need for developing robust biomarkers to inform treatment decisions and identify patients who are likely to respond.
18 CitationsSource
#1Aeen AsgharH-Index: 4
#2Daniel ParkerH-Index: 7
Last. Alexander KutikovH-Index: 52
view all 15 authors...
2 CitationsSource
Cited By1
The search for new diagnostic tests for cancer or ways to improve existing tests is primarily driven by the desire to identify the disease as early as possible. In this report, we summarize the current knowledge of the most promising diagnostic protein bladder cancer (BC) markers reported over the last decade. Unfortunately, analysis of published data suggests that a reliable, highly sensitive biomarker test-system based on ELISA for detecting BC has not yet been developed. The use of more sensi...